IL-10 Compositions with Immune Checkpoint Pathway Inhibitors for Cancer Treatment

ChangeBridge: Patent Grants - Pharma (A61K)

Published March 31st, 2026

Detected March 31st, 2026

Summary

USPTO granted Eli Lilly and Company Patent US12589134B2 covering compositions and methods for treating neoplastic diseases using IL-10 agents in combination with immune checkpoint pathway inhibitors. The patent contains 26 claims and names Martin Oft as inventor.

View original document View source feed page

What changed

USPTO issued Patent US12589134B2 to Eli Lilly and Company on March 31, 2026, covering a method for treating neoplastic diseases by administering an IL-10 agent combined with at least one modulator of an immune checkpoint pathway. The patent specifically addresses treatment of neoplasms with low or intermediate tumor mutation burden, low or intermediate expression of immune checkpoint molecules, or metastatic neoplastic disease.

This is a routine patent grant notification creating no compliance obligations. Pharmaceutical companies developing similar combination therapies should conduct freedom-to-operate analyses to assess potential patent infringement risks. Licensing discussions with Eli Lilly may be warranted for parties seeking to develop competing IL-10 and checkpoint inhibitor combinations.

Source document (simplified)

← USPTO Patent Grants

Compositions and methods of use of interleukin-10 in combination with immune check-point pathway inhibitors

Grant US12589134B2 Kind: B2 Mar 31, 2026

Assignee

Eli Lilly and Company

Inventors

Martin Oft

Abstract

The present disclosure provides a method for the treatment of neoplastic disease in a mammalian subject the method comprising the administration of an IL-10 agent in combination with the administration of at least one modulator of at least one immune checkpoint pathway. The present disclosure further provides a method for the treatment of neoplastic disease wherein the neoplasm has a low or intermediate tumor mutation burden, low or intermediate level of expression of the immune checkpoint molecule, or metastatic neoplastic disease.

CPC Classifications

A61K 38/2066 A61K 39/3955 A61K 39/4636

Filing Date

2023-10-17

Application No.

18488796

Claims

View original document →

Named provisions

Compositions and Methods of Use of Interleukin-10 Treatment of Neoplastic Disease Combination with Immune Checkpoint Pathway Inhibitors Low or Intermediate Tumor Mutation Burden